Kyverna Files First Autoimmune CAR-T BLA, Cash Falls to $170.6M

Kyverna Therapeutics (Nasdaq: KYTX) said on 12 November 2026 that it completed its rolling Biologics License Application to the U.S. Food and Drug Administration for miv-cel in stiff person syndrome, requesting priority review under its Regenerative Medicine Advanced Therapy designation. The company also reported third quarter results: a net loss of $41.9 million, or $0.68 per share, on research and development expenses of $27.0 million and general and administrative expenses of $15.9 million. Cash, cash equivalents and marketable securities stood at $170.6 million at 30 September 2026, down from $279.3 million at 31 December 2025.

Context — why an autoimmune CAR-T filing matters now

Kyverna is asking the FDA to review the first CAR T-cell therapy BLA in autoimmune disease. If approved, miv-cel would become the first approved therapy for SPS, according to the company's own framing of the opportunity. The filing rests on the KYSA-8 registrational trial, which the company said delivered positive data across primary and secondary endpoints.

The submission moves Kyverna from a clinical-stage story into a regulatory and launch-execution story. That shift changes what investors are underwriting: not trial design risk, but review timing, label scope and commercial build-out cost.

The report gives the company's own comparable. Cash fell $108.7 million over nine months, while net loss narrowed to $120.0 million for the nine months ended 30 September 2026 from $123.5 million a year earlier. The company said its cash position, plus amounts available for draw from an amended Oxford Finance loan facility, is expected to fund operations into 2028.

The trigger for the filing is the data package itself. Kyverna said one-year SPS results presented at MS Toronto in October 2026 showed miv-cel reversed disability and held durable efficacy, with nearly all patients off chronic immunotherapies after a single dose. The primary KYSA-8 analysis was published in JAMA Neurology, and the company said additional one-year biomarker data will be presented at ASH 2026.

Macro conditions are not a stated factor in the report. No rate, yield or index level appears in the filing language, so none is asserted here.

Data — what the numbers show

The quarter's cost structure inverted the year-over-year trend. R&D fell to $27.0 million from $30.5 million, while G&A rose to $15.9 million from $8.3 million. Total operating expenses climbed to $42.9 million from $38.7 million, driven entirely by the administrative line.

Metric	Q3 2026	Q3 2025
R&D expense	$27.0M	$30.5M
G&A expense	$15.9M	$8.3M
Total operating expenses	$42.9M	$38.7M
Net loss	$41.9M	$36.8M
Net loss per share	$0.68	$0.85

Net loss per share improved despite the wider net loss because weighted-average shares outstanding rose to 61,960,238 from 43,415,367. Interest income fell to $1.7 million from $2.0 million, and interest expense rose to $728,000 from $7,000, reflecting the loan facility.

On the balance sheet, total assets fell to $189.4 million from $293.8 million, and stockholders' equity dropped to $133.2 million from $232.3 million. Current liabilities fell to $25.1 million from $36.5 million. Loan payable, net, was $25.0 million versus $24.7 million.

Nine-month figures give the fuller burn picture: R&D of $81.9 million versus $103.7 million, G&A of $41.9 million versus $26.8 million, and total other income of $3.8 million versus $7.0 million. The company did not disclose the terms of the amended Oxford Finance facility.

Analysis — what it means for markets and sectors

Kyverna's filing tests whether the FDA will accept an autoimmune CAR-T application on a priority clock. A priority review designation shortens the review window relative to standard review, which would pull the potential 2027 U.S. launch the company describes closer to the filing date. The company did not disclose the requested or expected action date.

The G&A jump is the number to watch. Launch readiness — hiring commercial leaders, activating treatment centers, building a patient support and reimbursement network, and recruiting field sales and medical specialists — is a fixed cost incurred before any revenue. If approval slips, that spending continues against a shrinking cash base.

The R&D decline is consistent with a pipeline narrowing toward late-stage assets. Kyverna said it deprioritized the KYV-102 program to concentrate on miv-cel. That reduces the number of shots on goal while lowering near-term development spend.

The clearest counter-argument sits in the gMG program. The KYSA-6 Phase 3 trial for generalized myasthenia gravis is not expected to complete enrollment until mid-2027. The SPS filing is therefore carrying the entire near-term commercial thesis, and a single regulatory outcome drives the story.

Exposure runs through cell-therapy manufacturing and autoimmune neurology. The report names no partner, manufacturer or peer ticker, so no comparable company is asserted here. Positioning is a two-sided setup: holders of the launch thesis need a priority review grant and a clean label, while skeptics point to the cash decline and the pre-revenue commercial build.

Outlook — what to watch next

Three catalysts sit on the calendar the company itself laid out. First, the FDA's response to the priority review request, which the company did not date. Second, the ASH 2026 presentation of additional one-year biomarker data from KYSA-8. Third, the mid-2027 target for completing KYSA-6 enrollment in gMG.

Kyverna also said it expects to share its development strategy in progressive multiple sclerosis by early 2027, following an RMAT designation in non-active secondary progressive MS. That decision point matters because it determines whether the franchise adds a third late-stage indication or stays concentrated in two.

On the balance sheet, the relevant threshold is the 2028 runway the company projects. Quarterly operating expenses near $43 million against $170.6 million in cash define how much room exists before the loan facility becomes the primary funding source. The report gives no revenue guidance and no approval probability.

Frequently Asked Questions

What does the Kyverna BLA submission mean for retail investors?

It moves Kyverna from a data-driven story to a regulatory one. The company reported a $41.9 million quarterly net loss and $170.6 million in cash, and said that funds operations into 2028 with the loan facility. The key variable for anyone tracking the stock is whether the FDA grants priority review, which the company requested but has not received.

Why did Kyverna's general and administrative costs jump in Q3 2026?

The company attributed the increase to commercial readiness. G&A rose to $15.9 million from $8.3 million a year earlier, while R&D fell to $27.0 million from $30.5 million. Kyverna said it is hiring commercial leaders, activating treatment centers and building a patient support and reimbursement network ahead of a potential 2027 U.S. launch of miv-cel.

What happens next for Kyverna's pipeline if miv-cel is not approved?

The report does not address that scenario. The nearest disclosed milestones are the ASH 2026 biomarker presentation, the mid-2027 KYSA-6 enrollment completion in gMG, and a progressive multiple sclerosis development strategy expected by early 2027. Kyverna also deprioritized KYV-102, leaving miv-cel as the lead asset across all disclosed indications.

Bottom Line

Kyverna's first-in-class autoimmune CAR-T filing is now the FDA's call, and the company is spending to launch before it has approval.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.